Additional studies, involving several other K → Q and K → R acetylation and deacetylation mutants, in pertinent cells and primary cultures of breast tumor epithelial cells, could evolve therapeutic implications targeting StAR in controlling intra-tumoral E2 accumulation for combating hormone-sensitive BC. This evidence concerns the gene STAR and breast neoplasm.